SOUTH SAN FRANCISCO, Calif., March 1, 2022 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a synthetic lethality focused precision medicine oncology company committed to the discovery and development of targeted therapeutics, announced its participation in investor conferences in March 2022.
Guggenheim 3rd Annual Healthy Altitudes CEO Summit Panel
Thursday, March 10 at 9:00am ET
Participation by Yujiro Hata, Chief Executive Officer, IDEAYA Biosciences, moderated by Dan Skovronsky, M.D. Ph.D. CSO, Eli Lilly with host Seamus Fernandez, Senior Managing Director and Global Biopharma Analyst, Guggenheim Securities
Oppenheimer Targeted Oncology Panel
Monday, March 14, 10:00am ET
Participation by Yujiro Hata, Chief Executive Officer, IDEAYA Biosciences, hosted by Kevin DeGeeter Managing Director and Senior Analyst, Biotechnology and Diagnostics, Oppenheimer
34th Annual Roth Conference
Monday, March 14, 2022 at 6:00pm ET
Fireside chat with Paul Stone, Chief Financial Officer, IDEAYA Biosciences, hosted by Zegbeh Jallah Ph.D. Managing Director, Research Analyst, Biotechnology Roth Capital Partners
Oppenheimer's 32nd Annual Healthcare Conference
Wednesday, March 16, 2022 at 10:40am ET
Presentation by Yujiro Hata, Chief Executive Officer, IDEAYA Biosciences
A live audio webcast of the event will be available, as permitted by conference host, at the "Investors/News and Events/Investor Calendar" section of the IDEAYA website at https://ir.ideayabio.com/events. A replay of available webcasts will be accessible for 30 days following the live event.
About IDEAYA Biosciences
IDEAYA is a synthetic lethality-focused precision medicine oncology company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. IDEAYA's approach integrates capabilities in identifying and validating translational biomarkers with drug discovery to select patient populations most likely to benefit from its targeted therapies. IDEAYA is applying its early research and drug discovery capabilities to synthetic lethality – which represents an emerging class of precision medicine targets.
This press release contains forward-looking statements, including, but not limited to, statements related to participation in and/or presentation at certain investor relations events. IDEAYA undertakes no obligation to update or revise any forward-looking statements. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to the business of IDEAYA in general, see IDEAYA's Quarterly Report on Form 10-Q filed on November 15, 2021 and any current and periodic reports filed with the U.S. Securities and Exchange Commission.
SOURCE IDEAYA Biosciences, Inc.